Accueil   Diary - News   All news ERYTECH, allowance for patent

ERYTECH, allowance for patent

ERYTECH, a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application No. 12/672,094 entitled “Composition and Therapeutic Anti-tumor Vaccine.

Read the press release




Afficher l'image d'origine